MedTrace Logo

Effect of Gymnema Sylvestre on Metabolic Syndrome and Insulin

NCT02370121 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2019-06-18

Study results available
· View outcomes & findings →

Summary

Gymnema sylvestre has demonstrated promising effects in the treatment of obesity, dyslipidemia, hypertension, insulin secretion, among others. The above mentioned findings show that Gymnema sylvestre has an excellent potential for the prevention and treatment of metabolic syndrome.

Conditions

  • Metabolic Syndrome

Interventions

DRUG

Placebo

Capsules of 300 mg two times per day before breakfast and dinner a total dose of 600 mg per day. During 90 days.

DRUG

Gymnema Sylvestre

Capsules of 300 mg of calcined magnesium two times per day before breakfast and dinner a total dose of 600 mg per day. During 90 days.

Sponsors & Collaborators

  • University of Guadalajara

    lead OTHER

Principal Investigators

  • Esperanza Martínez, PhD · Institute of Experimental and Clinical Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2014-12-31
Completion
2015-01-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02370121 on ClinicalTrials.gov